Thrombotic microangiopathy in renal transplantation, tacrolimus as a causative agent

Descripción del Articulo

Thrombotic microangiopathy (TMA) is an unusual complication associated to the use of tacrolimus in renal transplantation. This condition may be related to infections, antibody-mediated rejection (AMR), disease recurrence or de novo TMA, and toxicity of calcineurin inhibitors. Generally, this conditi...

Descripción completa

Detalles Bibliográficos
Autores: Rodriguez-Mori, Juan E., Mego-Arellan, Denese C., Sumire-Umeres, Julia, Asato-Higa, Carmen, Rodríguez-Mori, Juan E.
Formato: artículo
Fecha de Publicación:2020
Institución:Colegio Médico del Perú
Repositorio:Acta Médica Peruana
Lenguaje:español
OAI Identifier:oai:amp.cmp.org.pe:article/1056
Enlace del recurso:https://amp.cmp.org.pe/index.php/AMP/article/view/1056
Nivel de acceso:acceso abierto
Materia:Microangiopatías trombóticas
Tacrolimus
Trasplante renal
Thrombotic microangiopathies
Kidney transplantation
id REVCMP_2bc0640c69de5006de5cd924e50639a6
oai_identifier_str oai:amp.cmp.org.pe:article/1056
network_acronym_str REVCMP
network_name_str Acta Médica Peruana
repository_id_str .
spelling Thrombotic microangiopathy in renal transplantation, tacrolimus as a causative agentMicroangiopatía trombótica en el trasplante renal, el tacrolimus como causanteRodriguez-Mori, Juan E.Mego-Arellan, Denese C.Sumire-Umeres, JuliaAsato-Higa, CarmenRodríguez-Mori, Juan E.Mego-Arellan, Denese C.Sumire-Umeres, JuliaAsato-Higa, CarmenMicroangiopatías trombóticasTacrolimusTrasplante renalThrombotic microangiopathiesTacrolimusKidney transplantationThrombotic microangiopathy (TMA) is an unusual complication associated to the use of tacrolimus in renal transplantation. This condition may be related to infections, antibody-mediated rejection (AMR), disease recurrence or de novo TMA, and toxicity of calcineurin inhibitors. Generally, this condition presents in non-complete forms, which makes diagnosis difficult, and irreversible lesions may supervene. This case features the presence of a viral infection, and data suggesting rejection with the concomitant tacrolimus use. Therapy includes plasmapheresis and the use of monoclonal antibodies such as eculizumab. Nonetheless, in this particular case suspending therapy or switching from tacrolimus to another agent were good cost-effective measures.La microangiopatía trombótica (MAT) es una complicación poco frecuente asociada al uso de tacrolimus en el trasplante renal. Puede estar relacionado a infecciones, rechazo mediado por anticuerpos (RMA), recurrencia de enfermedad o MAT de novo y a toxicidad por inhibidores de la calcineurina. Por lo general, se presenta como formas incompletas, lo que hace difícil su diagnóstico, por lo que puede provocar lesiones irreversibles. El caso presentado comparte la presencia de infección viral, datos sugerentes de rechazo concomitantemente con el uso de tacrolimus. El tratamiento incluye plasmaferesis y anticuerpos monoclonales como eculizumab. Sin embargo, en el caso presentado la suspensión o cambio del tacrolimus fue una medida más costo-efectiva.Colegio Médico del Perú2020-12-27info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://amp.cmp.org.pe/index.php/AMP/article/view/105610.35663/amp.2020.374.1056ACTA MEDICA PERUANA; Vol. 37 No. 4 (2020): October - DecemberACTA MEDICA PERUANA; Vol. 37 Núm. 4 (2020): Octubre-Diciembre1728-59171018-8800reponame:Acta Médica Peruanainstname:Colegio Médico del Perúinstacron:CMPspahttps://amp.cmp.org.pe/index.php/AMP/article/view/1056/1243Copyright (c) 2020 ACTA MEDICA PERUANAinfo:eu-repo/semantics/openAccessoai:amp.cmp.org.pe:article/10562024-07-26T07:32:27Z
dc.title.none.fl_str_mv Thrombotic microangiopathy in renal transplantation, tacrolimus as a causative agent
Microangiopatía trombótica en el trasplante renal, el tacrolimus como causante
title Thrombotic microangiopathy in renal transplantation, tacrolimus as a causative agent
spellingShingle Thrombotic microangiopathy in renal transplantation, tacrolimus as a causative agent
Rodriguez-Mori, Juan E.
Microangiopatías trombóticas
Tacrolimus
Trasplante renal
Thrombotic microangiopathies
Tacrolimus
Kidney transplantation
title_short Thrombotic microangiopathy in renal transplantation, tacrolimus as a causative agent
title_full Thrombotic microangiopathy in renal transplantation, tacrolimus as a causative agent
title_fullStr Thrombotic microangiopathy in renal transplantation, tacrolimus as a causative agent
title_full_unstemmed Thrombotic microangiopathy in renal transplantation, tacrolimus as a causative agent
title_sort Thrombotic microangiopathy in renal transplantation, tacrolimus as a causative agent
dc.creator.none.fl_str_mv Rodriguez-Mori, Juan E.
Mego-Arellan, Denese C.
Sumire-Umeres, Julia
Asato-Higa, Carmen
Rodríguez-Mori, Juan E.
Mego-Arellan, Denese C.
Sumire-Umeres, Julia
Asato-Higa, Carmen
author Rodriguez-Mori, Juan E.
author_facet Rodriguez-Mori, Juan E.
Mego-Arellan, Denese C.
Sumire-Umeres, Julia
Asato-Higa, Carmen
Rodríguez-Mori, Juan E.
author_role author
author2 Mego-Arellan, Denese C.
Sumire-Umeres, Julia
Asato-Higa, Carmen
Rodríguez-Mori, Juan E.
author2_role author
author
author
author
dc.subject.none.fl_str_mv Microangiopatías trombóticas
Tacrolimus
Trasplante renal
Thrombotic microangiopathies
Tacrolimus
Kidney transplantation
topic Microangiopatías trombóticas
Tacrolimus
Trasplante renal
Thrombotic microangiopathies
Tacrolimus
Kidney transplantation
description Thrombotic microangiopathy (TMA) is an unusual complication associated to the use of tacrolimus in renal transplantation. This condition may be related to infections, antibody-mediated rejection (AMR), disease recurrence or de novo TMA, and toxicity of calcineurin inhibitors. Generally, this condition presents in non-complete forms, which makes diagnosis difficult, and irreversible lesions may supervene. This case features the presence of a viral infection, and data suggesting rejection with the concomitant tacrolimus use. Therapy includes plasmapheresis and the use of monoclonal antibodies such as eculizumab. Nonetheless, in this particular case suspending therapy or switching from tacrolimus to another agent were good cost-effective measures.
publishDate 2020
dc.date.none.fl_str_mv 2020-12-27
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://amp.cmp.org.pe/index.php/AMP/article/view/1056
10.35663/amp.2020.374.1056
url https://amp.cmp.org.pe/index.php/AMP/article/view/1056
identifier_str_mv 10.35663/amp.2020.374.1056
dc.language.none.fl_str_mv spa
language spa
dc.relation.none.fl_str_mv https://amp.cmp.org.pe/index.php/AMP/article/view/1056/1243
dc.rights.none.fl_str_mv Copyright (c) 2020 ACTA MEDICA PERUANA
info:eu-repo/semantics/openAccess
rights_invalid_str_mv Copyright (c) 2020 ACTA MEDICA PERUANA
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Colegio Médico del Perú
publisher.none.fl_str_mv Colegio Médico del Perú
dc.source.none.fl_str_mv ACTA MEDICA PERUANA; Vol. 37 No. 4 (2020): October - December
ACTA MEDICA PERUANA; Vol. 37 Núm. 4 (2020): Octubre-Diciembre
1728-5917
1018-8800
reponame:Acta Médica Peruana
instname:Colegio Médico del Perú
instacron:CMP
instname_str Colegio Médico del Perú
instacron_str CMP
institution CMP
reponame_str Acta Médica Peruana
collection Acta Médica Peruana
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1843978944342130688
score 13.263243
Nota importante:
La información contenida en este registro es de entera responsabilidad de la institución que gestiona el repositorio institucional donde esta contenido este documento o set de datos. El CONCYTEC no se hace responsable por los contenidos (publicaciones y/o datos) accesibles a través del Repositorio Nacional Digital de Ciencia, Tecnología e Innovación de Acceso Abierto (ALICIA).